Alterity Therapeutics to Present Iron Accumulation and Phase 3 Plans at Three May Conferences
Alterity Therapeutics will present quantitative susceptibility mapping findings on iron accumulation in early MSA at ISMRM in Cape Town on May 12 and randomized Phase 2 ATH434 data at MDSANZ in Sydney May 15-17. On May 18 in London, the CEO will discuss ATH434 clinical update and Phase 3 planning.
1. ISMRM Oral Presentation Details
On May 12 in Cape Town, Paula Trujillo, PhD, will deliver an oral presentation titled “Quantitative Susceptibility Mapping Detects Progressive Iron Accumulation in Early MSA,” highlighting QSM imaging biomarkers in multiple system atrophy.
2. MDSANZ Poster on Phase 2 ATH434 Data
From May 15-17 in Sydney, Daniel Claassen, MD, MS, will present poster data from the randomized, double-blind, placebo-controlled Phase 2 ATH434 study using CSF neurofilament light as a covariate to assess efficacy signals.
3. MSA Symposium Phase 3 Planning Update
On May 18 in London, CEO David Stamler will outline ATH434 clinical progress and Phase 3 pivotal trial planning, marking the company’s next step toward registration-enabling studies in MSA.
4. Company Outlook and Phase 3 Trial Preparation
These presentations reinforce Alterity’s clinical stage momentum in MSA, build investigator awareness ahead of the Phase 3 pivotal trial initiation, and support regulatory engagement for ATH434.